Announcement on Receipt of the Drug Clinical Trial Approval Notice
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Receipt of the Drug Clinical Trial Approval Notice
Filed with SSE · Stock code 600276 ·
6ix is reading this filing.
View original source (Shanghai Stock Exchange)Jiangsu Hengrui Pharmaceuticals Co., Ltd. on 6ix
Story so far
Earlier from Jiangsu Hengrui Pharmaceuticals
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Indicative Announcement on Acceptance by the EMA of the Application for Drug Marketing Authorization
- (600276)"JIANGSU HENGRUI PHARMACEUTICALS CO., LTD."Announcement on Progress in Repurchasing A-Shares
- Jiangsu Hengrui Pharmaceuticals: Hengrui Pharma Announces EMA Validation of Marketing Authorisation Application for Wevdury (fuzuloparib) in Combination with Abiraterone for Metastatic Castration-Resistant Prostate Cancer
- Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
Follow Jiangsu Hengrui Pharmaceuticals into a list and get an email when it puts out news.
Follow Jiangsu Hengrui Pharmaceuticals